Intravenous Immunoglobulin (5%)
Drug timelines are a Plus or Pro feature.
2 regulatory and trial events tracked for Intravenous Immunoglobulin (5%), covering 2017-11-13 to 2026-04-08. Get the full timeline:
Most recent: Clinical Trial Update: An Open-label Study of Intravenous Immunoglobulin (5%) for the Treatment of Primary Immune Thrombocytopenia [Phase 3]